# OnCo record nct05261399 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05261399/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05261399", "NCT05261399" ;
  schema:name "Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment"@en ;
  schema:alternateName "SAFFRON"@en ;
  schema:description "A phase 3 trial of Savolitinib, Osimertinib, Pemetrexed, Cisplatin and Carboplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05261399/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05261399> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-08-03" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .